Letter to the Editor

References 

1. Davidson MS, Fox KM, Gandhi SK, Ohsfeldt RL, McKenney JM. Medical management of patients before the incidence of a cardiovascular event. J Clin Lipidol. 2009;3:315–321
   • Abstract
   • Full Text
   • Full-Text PDF (130 KB)
   • CrossRef
2. Feeman WE. The Bowling Green Study of the primary and secondary prevention of atherosclerosis: descriptive analysis, findings, applications and conclusions. Ohio J Sci. 1992;92:153–181
3. Feeman WE. The Bowling Green Study of the primary and secondary prevention of atherosclerotic disease: update 1991-1993. Ohio J Sci. 1994;94:105–112
4. Feeman WE. Prediction of the population at risk of atherothrombotic disease. Exp Clin Cardiol. 2004;9:235–241
5. Feeman WE. The role of cigarette smoking in atherosclerotic disease: an epidemiologic analysis. J Cardiol Risk. 1999;6:333–336
6. Feeman WE Jr. The Best Lipid Predictor. Presented at the Fourteenth International Symposium on Atherosclerosis; 2006; Rome.
7. Feeman WE Jr. Framingham Risk Score vs. Cholesterol Retention Fraction in Predicting the Population at Risk of Atherothrombotic Disease. Presented at the International Symposium on Atherosclerosis; 2009; Boston.
8. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcome Trial-Lipids Lowering Arm (ASCOT-LLA): a Multicentre Randomised Controlled Trial. Lancet. 2003;361:1149–1158
   • Abstract
   • Full Text
   • Full-Text PDF (196 KB)
   • CrossRef
9. Feeman WE. Prediction of Angiographic Stabilization/Regression of Coronary Atherosclerosis by a Risk Factor Graph. J Cardiol Risk. 2000;7:415–423
10. Gotto AM. Lipid lowering, regression, and coronary events. A review of the interdisciplinary council on lipids and cardiovascular risk intervention, Seventh Council Meeting. Circulation. 1995;92:646–656
    • MEDLINE